Considering that ERBB2 and HER2 are both confirmed molecular subtyping biomarkers for breast cancer [71], the functional links of the two genes with our predicted gene indicate that BCL9 may also be a potential biomarker at the methylation level, thereby validating the efficacy and accuracy of our prediction. The gene discussed is ERBB2; the disease is breast carcinoma.